CNS targeting AAV vectors and methods of use thereof
US-9102949-B2 · Aug 11, 2015 · US
US11041171B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11041171-B2 |
| Application number | US-202016682712-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 13, 2019 |
| Priority date | Nov 13, 2001 |
| Publication date | Jun 22, 2021 |
| Grant date | Jun 22, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.
Opening claim text (preview).
The invention claimed is: 1. A method of generating a recombinant adeno-associated virus (AAV) comprising culturing a host cell containing: (a) a molecule encoding the AAV vp1 capsid protein having a sequence of amino acids 1 to 738 of SEQ ID NO: 85, or a sequence which is at least 95% identical to the full length of amino acids 1 to 738 of SEQ ID NO: 85; (b) a functional rep gene; (c) a nucleic acid molecule comprising at least one AAV inverted terminal repeat (ITR) and a non-AAV nucleic acid sequence encoding a gene product operably linked to sequences which direct expression of the product in a host cell; and (d) sufficient helper functions to permit packaging of the minigene into the AAV capsid protein under conditions which permit packaging of the minigene into the AAV capsid. 2. The method of claim 1 , wherein the sequence of the vp1 protein is at least 97% identical to the full length of amino acids 1 to 738 of SEQ ID NO: 85. 3. The method of claim 1 , wherein the sequence of the vp1 protein is at least 99% identical to the full-length of amino acids 1 to 738 of SEQ ID NO: 85. 4. The method of claim 1 , wherein the sequence of the vp1 protein is the full-length of amino acids 1 to 738 of SEQ ID NO: 85. 5. The method of claim 1 , wherein the gene product is alpha-1 antitrypsin, Factor VIII, Factor IX, ornithine transcarbamylase, glucose-6-phosphatase, phenylalanine hydroxylase, argininosuccinate synthetase, β-glucuronidase (GUSB), or a dystrophin protein. 6. The method of claim 1 , wherein the molecule is a nucleic acid molecule comprising nucleotides 844 to 3057 of SEQ ID NO: 27, or a nucleotide sequence at least 99% identical to nucleotides 844 to 3057 of SEQ ID NO: 27. 7. The method of claim 1 , wherein the rep gene is from AAV2. 8. A method of generating a recombinant adeno-associated virus (AAV) comprising culturing a host cell containing: (a) a molecule encoding the AAV vp2 capsid protein having a sequence of amino acids 138 to 738 of SEQ ID NO: 85, or a sequence which is at least 95% identical to the full length of amino acids 138 to 738 of SEQ ID NO: 85; (b) a functional rep gene; (c) a nucleic acid molecule comprising at least one AAV inverted terminal repeat (ITR) and a non-AAV nucleic acid sequence encoding a gene product operably linked to sequences which direct expression of the product in a host cell; and (d) sufficient helper functions to permit packaging of the minigene into the AAV capsid protein under conditions which permit packaging of the minigene into the AAV capsid. 9. The method of claim 8 , wherein the sequence of the vp2 protein is at least 97% identical to the full length of amino acids 138 to 738 of SEQ ID NO: 85. 10. The method of claim 8 , wherein the sequence of the vp2 protein is at least 99% identical to the full-length of amino acids 138 to 738 of SEQ ID NO: 85. 11. The method of claim 8 , wherein the sequence of the vp2 protein is the full-length of amino acids 138 to 738 of SEQ ID NO: 85. 12. The method of claim 8 , wherein the gene product is alpha-1 antitrypsin, Factor VIII, Factor IX, ornithine transcarbamylase, glucose-6-phosphatase, phenylalanine hydroxylase, argininosuccinate synthetase, β-glucuronidase (GUSB), or a dystrophin protein. 13. The method of claim 8 , wherein the molecule is a nucleic acid molecule comprising nucleotides 1255 to 3057 of SEQ ID NO: 27, or a nucleotide sequence at least 99% identical to nucleotides 1255 to 3057 of SEQ ID NO: 27. 14. The method of claim 8 , wherein the rep gene is from AAV2. 15. A method of generating a recombinant adeno-associated virus (AAV) comprising culturing a host cell containing: (a) a molecule encoding the AAV vp3 capsid protein having a sequence of amino acids 204 to 738 of SEQ ID NO: 85, or a sequence which is at least 95% identical to the full length of amino acids 204 to 738 of SEQ ID NO: 85; (b) a functional rep gene; (c) a nucleic acid molecule comprising at least one AAV inverted terminal repeat (ITR) and a non-AAV nucleic acid sequence encoding a gene product operably linked to sequences which direct expression of the product in a host cell; and (d) sufficient helper functions to permit packaging of the minigene into the AAV capsid protein under conditions which permit packaging of the minigene into the AAV capsid. 16. The method of claim 15 , wherein the sequence of the vp3 protein is at least 97% identical to the full length of amino acids 204 to 738 of SEQ ID NO: 85. 17. The method of claim 15 , wherein the sequence of the vp3 protein is at least 99% identical to the full-length of amino acids 204 to 738 of SEQ ID NO: 85. 18. The method of claim 15 , wherein the sequence of the vp3 protein is the full-length of amino acids 204 to 738 of SEQ ID NO: 85. 19. The method of claim 15 , wherein the gene product is alpha-1 antitrypsin, Factor VIII, Factor IX, ornithine transcarbamylase, glucose-6-phosphatase, phenylalanine hydroxylase, argininosuccinate synthetase, β-glucuronidase (GUSB), or a dystrophin protein. 20. The method of claim 15 , wherein the molecule is a nucleic acid molecule comprising nucleotides 1453 to 3057 of SEQ ID NO: 27, or a nucleotide sequence at least 99% identical to nucleotides 1453 to 3057 of SEQ ID NO: 27. 21. The method of claim 15 , wherein the rep gene is from AAV2.
Receptors; Cell surface antigens; Cell surface determinants · CPC title
mammalian · CPC title
regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE · CPC title
Drugs for disorders of the respiratory system · CPC title
Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.